Novocure (NVCR) Q2 2026 earnings review
Milestone Reached: Novocure Turns Adjusted EBITDA Positive
Novocure delivered its strongest quarter to date, characterized by accelerating revenue growth (+16% YoY to $183.6 million) and a historic pivot to positive Adjusted EBITDA ($10.8 million). The successful U.S. launch of Optune Pax for pancreatic cancer is driving active patient volume significantly higher, allowing management to raise full-year guidance for both top and bottom lines. While cash burn has practically halted, revenue recognition for new indications continues to lag patient starts due to expected reimbursement delays.
🐂 Bull Case
Adjusted EBITDA reversed from negative to $10.8M positive this quarter. Coupled with a raised full-year guidance of $0-15M, Novocure has proven its business model can scale profitably without extensive new capital.
Active patients on Optune Pax (pancreatic cancer) reached 285 in just its first full quarter, validating management's previous claims that physician demand is multiples higher than the previous lung cancer launch.
🐻 Bear Case
Despite 285 active patients on Optune Pax, recognized revenue was only $1.6M. This confirms that securing broad payer coverage will be a multi-year headwind before patient volumes translate into meaningful cash flow.
The NSCLC indication (Optune Lua) reached 207 patients globally, adding only about 40 sequentially. The adoption curve remains difficult, as previously noted by management regarding heavy competition from drug therapies.
⚖️ Verdict: 🟢
Bullish. The dual achievement of accelerating double-digit revenue growth and crossing the profitability threshold validates the company's long-term strategy. The fast uptake of Optune Pax overshadows the lingering struggles of Optune Lua.
Key Themes
Optune Pax Exceeding Early Expectations
Accelerating. The launch of Optune Pax for locally advanced pancreatic cancer is emerging as a massive growth driver. Active patients surged to 285 in the U.S. Further expanding the total addressable market, Novocure secured the CE Mark in Europe, launching first in Germany. This rapid adoption trajectory contrasts sharply with the historical struggles of the lung cancer indication.
Operating Leverage Kicking In
Reversing. For years, Novocure burned cash to build its infrastructure and run clinical trials. Now, total operating costs have decreased by 2% YoY to $153.0M, despite a 16% jump in revenue. R&D dropped 8% as major trials concluded, and G&A fell 9%. This operational discipline is the primary engine behind the newly achieved positive Adjusted EBITDA.
Core GBM Business Remains Resilient
Stable. The foundation of Novocure's business, Optune Gio for glioblastoma, continues to perform reliably. Global active patients reached 4,636, an 11% increase YoY. The geographic breakdown shows strong international execution offsetting any potential stagnation in the U.S., proving the core business can fund newer indication launches.
Gross Margin Boost is a Mirage
The reported Gross Margin expanded to 78% (from 74% a year ago). However, this headline number is misleading. Cost of revenues benefited from a one-time macro-related $4.9M tariff refund. If we exclude this benefit, the underlying gross margin was approximately 75%, which aligns perfectly with management's full-year guidance for the 'mid-70s'. Investors should not view 78% as the new baseline.
Reimbursement Lag on New Indications
A specific data point highlights a long-term risk: Optune Pax recorded 285 active patients but generated only $1.6M in recognized revenue for the quarter. This equates to minimal revenue per patient thus far. Management previously warned it would take 1 to 2 years to get routine coverage. Until Medicare and private payers update their guidelines, providing the device to patients carries immediate costs with delayed cash returns.
Optune Lua Adoption Grind
Decelerating. While active patients on Optune Lua (NSCLC) grew 51% YoY to 207, sequential growth is slow. The indication contributed just $5.4M in revenue across multiple countries (U.S., Germany, Japan). Compared to the aggressive uptake of Optune Pax, lung cancer remains a difficult commercial environment due to established drug competition and physician habit.
Other KPIs
Stable. Total liquidity barely moved from the end of Q1 ($441.8M). This implies that cash burn during the quarter was practically negligible (~$1.2M), a dramatic reversal from the heavy cash consumption seen in FY2025. This effectively removes near-term dilution risk.
Decelerating. R&D expenses declined 8% YoY from $55.8M. Management noted this was driven by lower direct clinical trial expenses from completed trials, validating the company's shift from a heavy clinical phase into a commercial execution phase.
Guidance
Accelerating. Raised from the previous range of $690 - $710 million. The new midpoint of $717.5M implies a ~9.5% YoY growth rate over FY25's $655M, confirming that momentum from Q1 and Q2 is expected to persist through the second half of the year.
Reversing. Significantly raised from the previous forecast of $(15)M to $0M. Achieving the midpoint ($7.5M) would mark the first profitable year on an Adjusted EBITDA basis since the aggressive expansion phase began, demonstrating excellent cost control alongside the new product launches.
Stable. Management maintained this collective range. With $7.0 million achieved in Q2 alone ($10.1 million YTD assuming Q1's $3.1M was entirely Lua), the company is on track to comfortably land within this range, though it highlights that the vast majority of FY26 revenue still relies on the core Optune Gio (GBM) franchise.
Key Questions
Optune Pax Revenue Conversion
With 285 active patients already on Optune Pax but only $1.6M recognized in Q2, what are the internal assumptions for the average time required to convert a new prescription into a reimbursed claim under current temporary coverage policies?
Gross Margin Normalization
Gross margin was a robust 78% this quarter, but benefited from a $4.9M tariff refund. As the mix of largely unreimbursed Optune Pax patients increases in the second half of the year, how much pressure should we expect on the underlying 'mid-70s' gross margin guidance?
Optune Lua Commercial Strategy
With Optune Pax showing immediate, strong traction, will the company further reallocate sales and marketing resources away from the slower-moving Optune Lua (NSCLC) launch in the U.S. to maximize the pancreatic cancer opportunity?